Literature DB >> 16439541

CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate.

Jinglin Sun1, Timothy Soos, Vineet N Kewalramani, Kristin Osiecki, Jian Hua Zheng, Laurie Falkin, Laura Santambrogio, Dan R Littman, Harris Goldstein.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-encoded Tat provides transcriptional activation critical for efficient HIV-1 replication by interacting with cyclin T1 and recruiting P-TEFb to efficiently elongate the nascent HIV transcript. Tat-mediated transcriptional activation in mice is precluded by species-specific structural differences that prevent Tat interaction with mouse cyclin T1 and severely compromise HIV-1 replication in mouse cells. We investigated whether transgenic mice expressing human cyclin T1 under the control of a murine CD4 promoter/enhancer cassette that directs gene expression to CD4(+) T lymphocytes and monocytes/macrophages (hu-cycT1 mice) would display Tat responsiveness in their CD4-expressing mouse cells and selectively increase HIV-1 production in this cellular population, which is infected primarily in HIV-1-positive individuals. To this end, we crossed hu-cycT1 mice with JR-CSF transgenic mice carrying the full-length HIV-1(JR-CSF) provirus under the control of the endogenous HIV-1 long terminal repeat and demonstrated that human cyclin T1 expression is sufficient to support Tat-mediated transactivation in primary mouse CD4 T lymphocytes and monocytes/macrophages and increases in vitro and in vivo HIV-1 production by these stimulated cells. Increased HIV-1 production by CD4(+) T lymphocytes was paralleled with their specific depletion in the peripheral blood of the JR-CSF/hu-cycT1 mice, which increased over time. In addition, increased HIV-1 transgene expression due to human cyclin T1 expression was associated with increased lipopolysaccharide-stimulated monocyte chemoattractant protein 1 production by JR-CSF mouse monocytes/macrophages in vitro. Therefore, the JR-CSF/hu-cycT1 mice should provide an improved mouse system for investigating the pathogenesis of various aspects of HIV-1-mediated disease and the efficacies of therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439541      PMCID: PMC1367149          DOI: 10.1128/JVI.80.4.1850-1862.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

Review 1.  Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS.

Authors:  Kenneth C Williams; William F Hickey
Journal:  Annu Rev Neurosci       Date:  2002-03-27       Impact factor: 12.449

Review 2.  HIV-1 pathogenesis.

Authors:  Mario Stevenson
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

3.  Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier.

Authors:  J M Weiss; S A Downie; W D Lyman; J W Berman
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1.

Authors:  Venkat S R K Yedavalli; Monsef Benkirane; Kuan-Teh Jeang
Journal:  J Biol Chem       Date:  2002-11-27       Impact factor: 5.157

5.  Human macrophages accumulate HIV-1 particles in MHC II compartments.

Authors:  Graça Raposo; Marilyn Moore; Donald Innes; Richtje Leijendekker; Andrew Leigh-Brown; Philippe Benaroch; Hans Geuze
Journal:  Traffic       Date:  2002-10       Impact factor: 6.215

6.  Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells.

Authors:  Yong-Hui Zheng; Hai-Feng Yu; B Matija Peterlin
Journal:  Nat Cell Biol       Date:  2003-07       Impact factor: 28.824

7.  Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication.

Authors:  Ozlem Equils; Marco L Schito; Hiase Karahashi; Zeynep Madak; Ayse Yarali; Kathrin S Michelsen; Alan Sher; Moshe Arditi
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

8.  HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages.

Authors:  Elena Izmailova; Frederic M N Bertley; Qian Huang; Norbert Makori; Christopher J Miller; Richard A Young; Anna Aldovini
Journal:  Nat Med       Date:  2003-01-21       Impact factor: 53.440

9.  Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

10.  In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model.

Authors:  Marco L Schito; Atul Goel; Yongsheng Song; John K Inman; Rasem J Fattah; William G Rice; Jim A Turpin; Alan Sher; Ettore Appella
Journal:  AIDS Res Hum Retroviruses       Date:  2003-02       Impact factor: 2.205

View more
  24 in total

Review 1.  Rodent models for HIV-associated neurocognitive disorders.

Authors:  Santhi Gorantla; Larisa Poluektova; Howard E Gendelman
Journal:  Trends Neurosci       Date:  2012-02-01       Impact factor: 13.837

2.  Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease.

Authors:  Briana Nixon; Esra Fakioglu; Martha Stefanidou; Yanhua Wang; Monica Dutta; Harris Goldstein; Betsy C Herold
Journal:  J Infect Dis       Date:  2013-08-29       Impact factor: 5.226

Review 3.  The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis.

Authors:  Ryan Colby Passaro; Jui Pandhare; Han-Zhu Qian; Chandravanu Dash
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-08       Impact factor: 4.147

4.  Induction of monocyte chemoattractant protein-1 (MCP-1/CCL2) gene expression by human immunodeficiency virus-1 Tat in human astrocytes is CDK9 dependent.

Authors:  Abdelkader Khiati; Olivier Chaloin; Sylviane Muller; Marc Tardieu; Philippe Horellou
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

5.  Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses.

Authors:  Christine Goffinet; Sarah Schmidt; Christian Kern; Lena Oberbremer; Oliver T Keppler
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

6.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

Review 7.  Animal models for HIV/AIDS research.

Authors:  Theodora Hatziioannou; David T Evans
Journal:  Nat Rev Microbiol       Date:  2012-12       Impact factor: 60.633

8.  Increased in vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysaccharides.

Authors:  Jinglin Sun; Jian Hua Zheng; Mengliang Zhao; Sunhee Lee; Harris Goldstein
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

9.  Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication.

Authors:  Sima Shelly Toussi; Aviva Joseph; Jian Hua Zheng; Monica Dutta; Laura Santambrogio; Harris Goldstein
Journal:  AIDS Res Hum Retroviruses       Date:  2009-11       Impact factor: 2.205

10.  Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide.

Authors:  Hongwei Wang; Jinglin Sun; Harris Goldstein
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.